HK Stock Market Move | REMEGEN (09995) increases more than 7%, Thai Tesaro's latest 3rd quarter clinical data is impressive.

REMEGEN (09995) rose more than 7%, as of the time of publication, it rose by 7.68% to 25.25 Hong Kong dollars with a trading volume of 376 million Hong Kong dollars. On the news front, on April 9, REMEGEN announced that its independently developed BLyS/APRIL dual-target fusion protein innovative drug telitacicept (telitacicept, RC18) for the treatment of generalized myasthenia gravis (gMG) Phase 3 study results appeared at the American Academy of Neurology (AAN) annual meeting with an "latest breakthrough research" oral presentation. Data shows that after 24 weeks of treatment with telitacicept, 98.1% of patients with myasthenia gravis showed an improvement of 3 points in the Myasthenia Gravis Activities of Daily Living (MG-ADL) score, and 87% of patients showed an improvement of 5 points in the Quantitative Myasthenia Gravis (QMG) score, with significant clinical significance. Currently, the application for the market approval of telitacicept for the treatment of generalized myasthenia gravis has been accepted by the Center for Drug Evaluation (CDE) in October 2024 and has been included in priority review. It is expected to be approved for the market in China in the second quarter of this year.